- Home
- ASLE vs ITRM Comparison
ASLE vs ITRM Comparison
Compare ASLE & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASLE
- ITRM
- Stock Information
- Founded
- ASLE 2008
- ITRM 2015
- Country
- ASLE United States
- ITRM Ireland
- Employees
- ASLE N/A
- ITRM N/A
- Industry
- ASLE Industrial Specialties
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- ASLE Consumer Discretionary
- ITRM Health Care
- Exchange
- ASLE Nasdaq
- ITRM Nasdaq
- Market Cap
- ASLE N/A
- ITRM 37.7M
- IPO Year
- ASLE N/A
- ITRM 2018
- Fundamental
- Price
- ASLE $6.69
- ITRM $1.08
- Analyst Decision
- ASLE Strong Buy
- ITRM Strong Buy
- Analyst Count
- ASLE 3
- ITRM 1
- Target Price
- ASLE $9.00
- ITRM $5.00
- AVG Volume (30 Days)
- ASLE 701.7K
- ITRM 300.3K
- Earning Date
- ASLE 05-07-2025
- ITRM 05-12-2025
- Dividend Yield
- ASLE N/A
- ITRM N/A
- EPS Growth
- ASLE N/A
- ITRM N/A
- EPS
- ASLE 0.11
- ITRM N/A
- Revenue
- ASLE $345,066,000.00
- ITRM N/A
- Revenue This Year
- ASLE $14.51
- ITRM N/A
- Revenue Next Year
- ASLE $18.41
- ITRM $150.10
- P/E Ratio
- ASLE $60.82
- ITRM N/A
- Revenue Growth
- ASLE 3.16
- ITRM N/A
- 52 Week Low
- ASLE $4.53
- ITRM $0.81
- 52 Week High
- ASLE $9.40
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- ASLE 36.24
- ITRM 32.84
- Support Level
- ASLE $6.63
- ITRM $1.05
- Resistance Level
- ASLE $7.59
- ITRM $1.16
- Average True Range (ATR)
- ASLE 0.38
- ITRM 0.08
- MACD
- ASLE -0.10
- ITRM -0.00
- Stochastic Oscillator
- ASLE 24.27
- ITRM 13.04
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.